Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

LFA-1 (CD11a) as a therapeutic target.

M R Nicolls1, R G Gill

  • 1Department of Medicine, University of Colorado Health Science Center, Denver, Colorado, USA. Mark.nicolls@uchsc.edu

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
|January 26, 2006
PubMed
Summary

Leukocyte function associated antigen-1 (LFA-1) is a key molecule in immune cell interactions. Anti-LFA-1 therapies show promise for augmenting other treatments by inducing regulatory tolerance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

C-kit-derived CD11b<sup>+</sup> cells are critical for cardiac allograft prolongation by autologous C-kit<sup>+</sup> progenitor cells.

Cellular immunology·2019
Same author

Disruption of Transplant Tolerance by an "Incognito" Form of CD8 T Cell-Dependent Memory.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Aspergillus-related pulmonary diseases in lung transplantation.

Medical mycology·2016
Same author

Simultaneously Targeting Myofibroblast Contractility and Extracellular Matrix Cross-Linking as a Therapeutic Concept in Airway Fibrosis.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

What's Hot, What's New From the 2016 American Transplant Congress.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Interferon Gamma and Contact-dependent Cytotoxicity Are Each Rate Limiting for Natural Killer Cell-Mediated Antibody-dependent Chronic Rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Medicine

Background:

  • Leukocyte function associated antigen-1 (LFA-1) is an early identified cell-surface molecule.
  • It functions as an integrin heterodimer crucial for T cell and antigen-presenting cell interactions.
  • LFA-1 plays multifaceted roles in leukocyte adhesion, activation, and trafficking within the immune response.

Purpose of the Study:

  • To explore the therapeutic potential of targeting LFA-1 in immune regulation.
  • To review the current status and future prospects of anti-LFA-1 therapies.
  • To highlight LFA-1's role beyond a classic adhesion molecule.

Main Methods:

  • Review of existing literature on LFA-1 function and therapeutic applications.
  • Analysis of studies involving monoclonal antibodies targeting LFA-1.

Related Experiment Videos

  • Examination of clinical trial data for anti-LFA-1 agents like Efalizumab.

    • Main Results:

    • Anti-LFA-1 monoclonal antibodies can induce regulatory tolerance in vivo.
    • Newer humanized anti-LFA-1 antibodies demonstrate potential in ongoing clinical trials.
    • Despite long-standing interest, anti-LFA-1 therapy is not yet a first-line treatment.

    Conclusions:

    • LFA-1 is a significant therapeutic target for modulating immune responses.
    • Anti-LFA-1 therapy holds promise as an adjunct to existing treatments.
    • Further research and clinical trials are needed to fully exploit LFA-1's immunotherapeutic potential.